Skip to content
Clinical Trials – home

Medical Center St. Ivan Rilski Chudotvorets 2010 EOOD

Verified siteinfo

Bulgaria A-A, Bulevard Vasil Levski 144, 4003 Plovdiv, Bulgaria

  • 5 trials recruiting
  • Chronic obstructive pulmonary disease · Acute myocardial infarction · COVID-19
  • Adults and children

About Specializations

Medical Center St. Ivan Rilski Chudotvorets 2010 EOOD in Plovdiv, Bulgaria specialises in clinical trials of conditions such as Chronic obstructive pulmonary disease, Acute myocardial infarction, COVID-19, Crohn's disease, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology

The medical center is at the forefront of gastroenterology, focusing on innovative treatments for ulcerative colitis. The center's research aims to improve the quality of life for patients with moderately to severely active ulcerative colitis through advanced therapeutic approaches.

  • Ulcerative Colitis
  • Inflammatory Bowel Disease
  • Clinical Remission Induction

By conducting cutting-edge research, the center contributes significantly to the development of new therapies that target the underlying mechanisms of inflammatory bowel diseases, offering hope for more effective management of these chronic conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
A-A, Bulevard Vasil Levski 1444003 PlovdivBulgaria
Recruiting now
5 trials
Conditions studied
10
Partner status
Verified site

More sites in PlovdivBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

9 clinical trials

Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

COVID-19

Recruiting

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Comparing liquid versus capsule forms of phosphatidylcholine in patients with alcoholic liver disease, chronic hepatitis B, and metabolic liver disease

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Opella Healthcare Group S.A.S.

Colitis ulcerative

Not recruiting

Study of RO7790121 Compared to Placebo for Treatment of Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.